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Abstract
When making a new diagnosis of melanoma, clinicians often ob-
tain imaging studies to rule out clinically occult distant disease. 
These studies range from inexpensive tests, such as chest radio-
graphs, to more expensive studies, such as PET/CT. The impetus for 
ordering these studies is usually the desire to identify potentially 
resectable distant disease, avoid surgery when curative resection 
is not possible, and assuage patient anxiety by showing that no 
evidence of distant disease is present. However, some detrimen-
tal aspects to these studies are less apparent, including cost and 
potential for false-positive findings. Although routine use seems 
reasonable, the true benefit of these studies depends on the prob-
ability of clinically occult disease being present, the likelihood that 
disease will be detected with the available technology, and the im-
pact of earlier detection on outcome. Contrary to current practice 
patterns, available evidence suggests that preoperative imaging 
studies are associated with significant costs and minimal benefit in 
most patients with melanoma. This article reviews available litera-
ture on the role of pretreatment imaging in patients with newly 
diagnosed cutaneous melanoma. (JNCCN 2009;7:XXX–XXX)
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adverse pathologic features, stage IB disease, and 
stage II disease, sentinel node biopsy is generally 
recommended. However, chest radiography (CXR) 
is considered optional and other imaging is not rou-
tinely recommended. The American Academy of 
Dermatology recommends no staging for patients 
with melanoma less than 4.0-mm thick,3 whereas 
the British Association of Dermatologists and Mela-
noma Study Group for the United Kingdom recom-
mend that patients with melanomas larger than 2.0 
mm undergo CXR, liver ultrasound, or CT of chest/
abdomen and pelvis.4 This recommendation has led 
to an extremely wide range of practices among clini-
cians caring for patients with melanoma.
Part of the difficulty in assessing the role of pre-
treatment imaging studies is defining the reason for 
ordering the test. Theoretically, the end point should 
be obvious: whether obtaining the study identi-
fies clinically occult disease, which could change 
planned management. This end point, however, is 
vague in many respects. Whether imaging findings 
would change the decision to proceed with sentinel 
node biopsy or completion node dissection in the 
case of a positive sentinel node is unclear.
It is a Herculean task to determine how often a 
study must meet this goal to be worthwhile, especially 
when balanced against the host of ensuing tests that 
indeterminate findings would generate, which are 
not without cost and morbidity. Although upfront 
imaging in all patients could provide not only base-
line information for future comparison studies but 
also comfort for most patients because examinations 
will likely be negative, it can also add significant cost 
and produce extreme anxiety for patients who have 
false-positive or indeterminate studies (Table 1).
This article reviews the role of pretreatment 
imaging in patients with cutaneous melanoma. Im-
portantly, the debate over the need for and extent 
of imaging in patients with cutaneous melanoma is 
limited to those without clinical suspicion of meta-
static disease. Focused imaging based on symptoms 
or clinical suspicion should be pursued as clini-
cally indicated. Any patient newly diagnosed with 
melanoma should undergo a thorough history and 
physical examination, with a detailed review of 
systems. Although comparatively crude when con-
sidering today’s available imaging technology, clin-
ical evaluation remains one of the most important 
modalities in identifying distant disease. Data from 
Imaging studies are frequently used in workups for 
patients with cancer to determine extent of disease 
before definitive treatment recommendations are 
made. Various imaging modalities may allow for more 
accurate staging or help detect clinically occult dis-
ease. In melanoma, imaging is focused on detecting 
occult sites of regional or distant disease. However, 
recommendations for preoperative imaging in mela-
noma must be considered in the context of sentinel 
lymph node biopsy, which is a minimally invasive 
procedure that provides excellent staging informa-
tion for patients with clinically localized disease.
Although characteristics of the primary tumor 
are important in determining stage and prognosis, 
the status of the sentinel node is the most impor-
tant prognostic factor in patients with intermedi-
ate-risk melanoma.1 Experts generally agree that 
sentinel node biopsy should be considered in pa-
tients with clinically node-negative melanoma of 
1-mm or greater Breslow thickness, but no consen-
sus exists as to what constitutes adequate or neces-
sary preoperative imaging. Therefore, the decision 
to pursue imaging depends on several factors, in-
cluding the probability of clinically occult disease 
being present, likelihood of disease detection given 
the limitations of imaging, potential for false-pos-
itive findings, and cost and morbidity of the study 
(including the cost of necessary follow-up examina-
tions or biopsies).
Consensus guidelines, including those from 
the National Comprehensive Cancer Network 
(NCCN), reflect the relative lack of certainty about 
benefits from pretreatment imaging for melanoma 
in asymptomatic patients.2 For stage IA disease with 
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studies on melanoma surveillance clearly show the 
importance of the history and physical in identify-
ing recurrences.5,6
Pretreatment Imaging of Patients with 
Clinically Node-Negative Melanoma
CXR
CXR is the most common imaging study obtained 
on patients newly diagnosed with melanoma. Argu-
ments for routine CXR include its low cost, the po-
tential need for a CXR in patients undergoing gen-
eral anesthesia, the benefit of having a baseline CXR 
if the patient has never had one before, and the fact 
that the lungs are among the most common visceral 
sites of spread.7,8
However, several studies have examined the rel-
ative worth of CXR in staging patients with melano-
ma, with little evidence to support its use. Khansur 
et al.9 found no true-positives and 2 false-positives 
among 72 patients with localized melanoma who 
underwent CXR. Ardizzoni et al.10 reported that all 
studies were normal among 93 patients with local-
ized melanoma who underwent pretreatment CXR. 
Zartman et al.11 also found no positive results among 
90 patients with asymptomatic localized disease who 
underwent CXR. Hofmann et al.5 reported on 661 
melanoma patients, of which 524 underwent a stag-
ing CXR, finding 23 false-positives and only 1 true-
positive. Cost-efficiency analysis showed that despite 
the low cost of CXR itself, it is a highly cost inef-
ficient examination. Yancowitz et al.12 reported that 
among 131 CXRs obtained among patients with T1b 
to T3b disease, 7 were suspicious or highly suspicious 
for melanoma. Of these, none was a true-positive, 
whereas 5 were false-positives (2 were lost to follow-
up). Hafner et al.13 found 4 of 100 patients had sus-
picious findings on preoperative CXR, all of which 
were PET negative and showed no progression on 
follow-up imaging.
Wang et al.14 prospectively examined the CXR 
findings of 210 patients with no clinical evidence of 
regional or distant disease. The mean Breslow depth 
was 1.38 mm, with it being less than 1 mm in 54% of 
patients and 1 mm or larger (range, 0.13–10 mm) in 
46% of patients. Of the 15 patients who had positive 
or equivocal melanoma-related results, none had 
confirmed lung metastases and only 1 ultimately de-
veloped metastatic disease. Thus, the false-positive 
rate of CXR (7%) was considerably higher than the 
rate of detecting asymptomatic pulmonary disease.
Terhune et al.15 retrospectively reviewed 1032 
asymptomatic patients with localized melanoma and 
found that 876 (85%) had an initial staging CXR 
performed. Of these patients, 5% had melanoma in 
situ, 62% had a Breslow depth less than 1.5 mm, and 
25% had a thickness between 1.5 and 4.0 mm (3% 
could not be staged). Overall, 130 (15%) had suspi-
cious findings that necessitated additional workup, 
whereas only 1 (0.1%) had a true-positive finding. 
When the study was limited to patients with mela-
nomas between 1.5 and 4.0 mm, the incidence of de-
tectable pulmonary disease was 0.4%.
However, the cost of this practice is not insig-
nificant, particularly in the absence of evidence that 
finding synchronous asymptomatic pulmonary dis-
ease improves survival. When follow-up studies are 
considered, the conservative financial cost of CXR 
for the 876 patients in the Terhune study was nearly 
$200,000 to find 1 patient with metastatic disease.16 
This, of course, does not take into consideration the 
anxiety and stress caused to the 14 patients with 
false-positive findings. Other studies have found 
more significant cost savings associated with forego-
ing CXR.17 Part of the argument against routine CXR 
is that when melanoma metastasizes to the lungs, it 
usually appears as multiple small foci, often less than 
the threshold necessary to be detected on CXR.18–20
Many have argued that CXR should be used sim-
ply because it is widely available, relatively inexpen-
sive and noninvasive.21,22 However, these variables 
do not satisfy an argument to continue its routine 
used. The available evidence clearly supports no role 
for obtaining routine CXRs in patients with clini-
cally node-negative melanoma with no symptoms of 
metastatic disease.
Imaging of the Regional Lymph Node Basin
Although sentinel lymph node biopsy is a well-estab-
lished minimally invasive procedure that provides 
accurate staging information, several investigators 
have examined the use of PET scanning for detect-
ing regional lymph nodes as an alternative to senti-
nel node biopsy, with sensitivity ranging from 0% to 
40%23–30 and a mean sensitivity of 16% to 17%.31,32 
The poor sensitivity is secondary to the fact that the 
volume of disease within the sentinel nodes is rarely 
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clinically node-negative melanoma. The role of ultra-
sound of the regional basin is still under investigation.
Body Imaging (CT or PET Scan)
Evidence supporting the routine use of CT scans 
among patients with newly diagnosed and unstaged 
melanoma is sparse. Only 2 studies specifically ex-
amine CT scans among patients in whom the nodal 
stage is unknown. Yancovitz et al.12 found that among 
57 of 158 patients with T1b through T3b disease 
who underwent CT scans, 24 suspicious areas identi-
fied. Among these, none were true-positives and 21 
were false-positives. For abdomen/pelvis CT scans, 
the results were similar: of the 11 suspicious findings 
identified, none were true-positives, whereas 10 were 
false-positives. Both suspicious findings on the 57 
head CTs also turned out to be false-positives. From 
this same dataset, 42 patients underwent PET/CT 
scans. Of 5 suspicious lesions identified, 1 was a true-
positive, whereas 3 were false-positives.
Buzaid et al.39 retrospectively looked at the use 
of CT scans among 151 asymptomatic patients with 
stage I, II, or III melanoma. Among the 29 patients 
who had suspicious findings, 24 were benign, 2 truly 
represented distant disease, and 3 had second pri-
mary tumors identified. The authors concluded that 
preoperative CT scans had minimal benefit, and 
indicated that additional and sometimes invasive 
studies were often needed that had the potential to 
increase patient anxiety.
Therefore, experts have suggested that more 
sensitive screening tests, despite their increased cost, 
may have a greater impact on screening patients 
with asymptomatic melanoma. In addition to its use 
in detecting regional disease, FDG-PET has been ex-
amined as a method of identifying distant disease in 
patients with clinically node-negative disease. Sev-
eral studies have touted the role of PET scanning in 
identifying distant disease; however, many of these 
positive findings include the detection of clinically 
palpable regional disease, and many studies include 
patients with early-stage and stage IV melanoma. 
When limited to patients with asymptomatic, clini-
cally node-negative melanoma, the use of FDG-PET 
is not strongly supported. Among 609 patients staged 
using FDG-PET (pooled from several studies), 38 pa-
tients (6%) had abnormal uptake outside the prima-
ry site or regional nodes, but only 1 had a true mela-
noma metastasis.32 Most patients had false-positive 
findings, although unrelated neoplastic processes 
Hafner et al.13 examined the role of ultrasound 
and PET scan for detecting regional metastases be-
fore sentinel lymph node biopsy in 100 patients with 
newly diagnosed melanoma greater than 1.0 mm. Ul-
timately, sentinel lymph node biopsy showed that 26 
patients had regional metastases; however, only 4 had 
disease greater than 2 mm. Ultrasound had a sensi-
tivity of 8%, specificity of 88%, positive predictive 
value of 18%, and negative predictive value of 73%. 
Ultrasound had 12 false-positives and was no better 
than clinical examination alone. PET did not have 
any false-positives, with a positive predictive value 
of 100%, but also had a sensitivity of only 8%. The 
combination did not fare much better. Despite these 
negative findings, the authors concluded that, along 
with physical examination, ultrasound may play a role 
in the detecting macroscopic lymph node metastases, 
although this only represented about 3% of patients.
Ultrasound of the axilla before sentinel lymph 
node biopsy, with ultrasound-guided fine needle as-
piration (FNA) of abnormal lymph nodes to confirm 
metastases, has been proven to be a useful approach 
to preoperative imaging in patients with breast can-
cer, and has become routine at many institutions.35 A 
similar approach was examined in melanoma. Rossi 
et al.36 prospectively examined preoperative regional 
ultrasound and FNA in 125 patients with melanoma 
greater than 1 mm undergoing sentinel lymph node 
biopsy. Ultimately, 31 patients were found to have 
regional metastases, with 12 detected by ultrasound-
guided FNA, for a sensitivity of 39%. Voit et al.37 
reported a higher sensitivity (79%) in a similar study. 
Based on these results, 10% and 16% of patients, re-
spectively, would have avoided sentinel lymph node 
biopsy and could have proceeded directly to comple-
tion lymph node dissection.
However, although Starritt et al.38 showed that 
targeted ultrasound examination of sentinel lymph 
nodes can detect metastatic melanoma deposits as 
small as approximately 4.5 mm in diameter, ultra-
sound of the regional basin cannot be considered 
cost-effective because most metastatic melanoma 
deposits in SLNs are considerably smaller than this 
at initial staging. The ongoing Multicenter Selective 
Lymphadenectomy Trial-II (MSLT-II) will provide 
further data on the efficacy of regional basin ultra-
sound before sentinel lymph node biopsy.
Available evidence supports no role for PET scan-
ning in identifying regional metastases in patients with 
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were identified in 10. In addition to being inferior 
to sentinel lymph node biopsy in detecting regional 
metastases, FDG-PET does not identify distant dis-
ease in asymptomatic patients.
The available evidence clearly supports no role for 
obtaining either routine CT or PET scan in patients 
with clinically node-negative melanoma without 
symptoms of metastatic disease. The staging informa-
tion obtained from intraoperative lymphatic mapping 
and sentinel node biopsy is likely to yield more accu-
rate and important prognostic information.40
An alternative strategy to routine testing is se-
lective testing using serum markers to identify pa-
tients with a higher risk for distant disease. One of 
the most common staging tests obtained in patients 
with melanoma is the serum lactate dehydrogenase 
(LDH) level. However, the efficacy of an elevated 
serum LDH in selecting patients who do not harbor 
metastases seems limited, because LDH only has 
prognostic value in stage IV disease. Wang et al.14 
prospectively examined the use of serum LDH in 
96 patients with melanoma 1 mm or greater. They 
found that elevations were not uncommon (15%) 
but did not lead to the detection of systemic disease.
Strobel et al.41 looked at limiting PET/CT scan 
only to patients with an elevated serum S-100B. 
This tumor marker may reflect the tumor burden and 
be useful for monitoring therapy in stage IV disease. 
Screening 165 patients with high-risk melanoma 
(defined as Breslow thickness > 4.0 mm, Clark level 
III or IV, or known resected metastases) yielded el-
evated serum S-100B levels in 47 patients. In this 
case, PET/CT performed well, correctly identifying 
metastases in 38 of these high-risk patients. How-
ever, S-100B did have a high number of false-posi-
tive results (17%). The authors recommend that, if 
S-100B is used, it should be repeated 2 to 4 weeks 
after the initial determination if no clinical evidence 
of distant disease is present. Additional studies are 
needed to confirm the efficacy of serum S-100B lev-
els in the routine staging of patients with melanoma.
Imaging After a Sentinel Lymph Node Biopsy
For patients with clinically node-negative melano-
ma, minimal evidence supports obtaining a CXR, 
CT scan, or PET scan before proceeding with wide 
excision and, if indicated, sentinel lymph node bi-
opsy. Patients with a positive sentinel lymph node 
will typically return to the operating room for a 
completion lymph node dissection, and therefore 
the question arises whether obtaining imaging at 
this juncture might be worthwhile. Patients with 
known nodal metastasis have a significantly higher 
risk for distant disease and represent a select group of 
patients with different treatment decisions.40 Several 
authors have examined the paradigm of proceeding 
with sentinel lymph node biopsy and limiting imag-
ing to patients with metastatic disease identified in 
the sentinel lymph node. Theoretically, discovery of 
occult distant metastases may preclude consideration 
of completion lymphadenectomy.42 However, studies 
have found that this imaging rarely changes plans for 
completion lymphadenectomy, and may actually de-
lay surgical treatment of regional disease.
Constantinidou et al.43 performed either PET 
scan or PET/CT in 30 patients with a positive sentinel 
lymph node and a melanoma of Breslow depth great-
er than 1 mm. Only 2 patients had positive findings 
and neither was melanoma-related. In a retrospective 
analysis of complete radiologic staging (CXR; CT of 
the chest, abdomen, and pelvis; and CT or MRI of the 
brain) in patients with positive sentinel lymph nodes, 
Miranda et al.42 found disease in 0.5%.
In an examination of CT and/or MRI in 270 as-
ymptomatic patients with a positive sentinel lymph 
node, Aloia et al.44 found disease in only 1.9%. Al-
though this analysis showed fewer false-positive 
results than previous studies, which the authors at-
tributed to improved technology, these were still 
frequent (12%). The authors proposed that further 
selection of patients for imaging based on the char-
acteristics of the primary tumor and sentinel lymph 
node (T4, ulceration, large sentinel lymph node tu-
mor burden) may be reasonable, as much to obtain 
baseline data in patients at high risk for recurrence as 
to find occult metastases.
Gold et al.45 retrospectively examined various 
radiologic studies obtained after a positive sentinel 
lymph node biopsy, and also found that indeterminate 
findings are high but distant disease is rarely found 
(3.7%). The impact, however, is more significant in 
patients with thick melanomas and macrometastases 
in the sentinel lymph node. Had CT or PET been 
limited only to patients with both thick melanomas 
and macrometastases in the sentinel lymph node, the 
frequency of positive studies would have been 16%.45
These retrospective studies have shown a lack of 
consistency in the types of imaging obtained. Com-
mon sites of metastases include the brain, lung, gas-
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tinel lymph nodes does not seem worthwhile, it may 
have a role in patients with thick primary tumors and 
a large tumor burden in the sentinel lymph node. 
Further prospective studies are needed to delineate 
the ideal subset of patients and cost-effectiveness of 
this approach.
Pretreatment Imaging of Patients With 
Clinically Node-Positive Melanoma or 
Those With Resectable Stage IV Disease
In an initial retrospective review of CT scans among 
patients with stage I, II, and III melanoma,39 pre-
operative CT scans identified synchronous distant 
disease in 1 of 23 who presented with clinically 
evident regional metastases. In a second study, the 
authors looked specifically at the CT results of 89 as-
ymptomatic patients with clinical locoregional dis-
ease and normal CXR and serum LDH levels.47 CT 
scanning identified metastatic disease in 6 patients 
(7%), whereas 20 (22%) had false-positive findings. 
Although the false-positive rate is concerning and 
trointestinal tract, and distant nodal basins. There-
fore, imaging studies are often used to examine the 
head, thorax, abdomen, and pelvis. In these studies, 
significant variation is seen in the imaging studies 
obtained. For example, brain imaging was variously 
performed with CT or MRI. CT scans included chest 
only, abdomen/pelvis only, or chest/abdomen/pelvis. 
CT scans of the neck were also occasionally obtained. 
However, head CT in asymptomatic patients, chest 
CT in patients with lower-extremity melanomas/
inguinal metastases, and pelvic CT in patients with 
axillary or cervical adenopathy are not indicated.46 
Functional imaging, such as 18FDG-PET scans, are 
frequently added to cross-sectional imaging studies. 
PET scans were used as a sole imaging modality or in 
conjunction with standard CT scans. However, with 
the advent of fusion PET-CT scans, which provide 
corresponding noncontrasted CT images, these are 
sometimes used instead of standard CT scans of the 
chest, abdomen, and pelvis.
Available evidence suggests that although rou-
































Figure 1 Proposed algorithm for preoperative imaging of patients with cutaneous melanoma based on the current evidence. 
CLND, completion lymph node dissection; SLN, sentinel lymph node; WLE, wide local excision.
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biopsies should be used to confirm suspicious find-
ings, CT scan was useful, particularly in patients 
with melanoma below the waist or in the head and 
neck region.
Kuvshinoff et al.46 reported similar findings when 
examining the role of CT in 347 patients with clinical 
stage III disease, finding detection and false-positive 
rates of 4.2% and 8.4%, respectively. Chest CT was 
particularly useful in patients with cervical adenop-
athy, whereas pelvic CT was most helpful in those 
with groin adenopathy. Minimal benefit was seen in 
patients with axillary adenopathy. The authors there-
fore recommended a selective approach to CT scans 
in patients with palpable adenopathy. Johnson et al.48 
examined CT scan use among patients with stage III 
disease, most of whom (99) had clinically node-pos-
itive disease, whereas elective node dissection iden-
tified 28 as having stage III disease. Although they 
found the yield of CT to be low, it was not insignifi-
cant and could alter treatment decisions.
Several authors have examined the use of PET 
scanning in staging patients with more advanced 
melanoma being considered for surgical resection. 
Tyler et al.49 examined 106 PET scans among 95 pa-
tients with clinically palpable nodal disease. Find-
ings on PET scans led to a change in the planned 
clinical management in 15% of cases. Damian et al.50 
reported a 22% alteration in patient management 
with PET scan. Brady et al.51 examined the combi-
nation of PET and CT scan in the preoperative set-
ting for patients with more advanced disease (AJCC 
stage IIC, III, or IV) and found that not only was 
the combination more effective than either modality 
alone but also the use of PET/CT led to a change in 
clinical management in 35% of patients. Other stud-
ies have also shown PET/CT to be superior to PET 
alone.52,53 In a retrospective analysis of 250 consecu-
tive patients, the combination of PET/CT detected 
more metastases than either PET or CT alone.53 
Strobel et al.54 prospectively examined PET scan-
ning with and without dedicated CT readout and 
found improved sensitivity, specificity, and accuracy 
with dedicated CT interpretation. They concluded 
that a dedicated analysis of CT data significantly im-
proves the results.
All of these studies, however, found that false-
positive findings were still significant. In several cas-
es, changes in management were made incorrectly 
because of false-positive findings.51,55 Therefore, his-
tologic confirmation of suspected metastases must be 
performed before the treatment plan is altered.
Conclusions
When a patient is newly diagnosed with melanoma, 
often the patient and physician have a strong desire 
to order preoperative staging studies to rule out dis-
tant disease before proceeding with curative surgery. 
However, the negative side to this approach is not 
immediately apparent, nor insignificant, and the evi-
dence supports a much more selective use of imag-
ing studies. Figure 1 presents a reasonable algorithm 
for radiographic staging of patients with melanoma 
based on the available evidence.
The single most important staging study in pa-
tients with newly diagnosed melanoma is a thorough 
history and physical examination. Any patient with 
signs or symptoms should undergo radiographic stag-
ing. Patients with evidence of nodal or in-transit 
metastases seem to benefit from radiographic staging 
before proceeding with resection, both in avoiding 
surgery in futile cases and planning the extent of the 
operation. Asymptomatic patients with clinically 
negative nodes derive minimal if any benefit from 
CXR, CT scan, PET scan, or regional ultrasound, 
and should proceed with wide local excision and 
sentinel lymph node biopsy.
Most patients with a positive sentinel lymph 
node should still proceed with completion node dis-
section without imaging; however, staging patients 
at a higher risk for distant disease may be reasonable, 
specifically those with thick primary tumors and a 
large tumor burden in the sentinel lymph node. It is 
important to remember the high false-positive rate 
associated with all of the available imaging studies 
and confirm any suspected areas of distant disease 
using biopsy before abandoning a potentially cura-
tive operation. Further prospective studies of preop-
erative imaging are necessary to identify the optimal 
subset of asymptomatic patients who should undergo 
preoperative imaging and define the most appropri-
ate studies.
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